21123 ⎘
Medicinal preparations containing antigens or antibodies; Viral antigens Rhabdoviridae, e.g. rabies virus
STABILIZATION OF VIRUS-BASED THERAPEUTIC AGENT
#2COMPOSITIONS AND METHODS FOR MAKING AND USING STABILIZED ENVELOPED VIRUSES BY SPRAY-DRYING AND LYOPHILIZATION
#3CATIONIC LIPID BASED COMPOSITION, FORMULATION AND USE FOR NUCLEIC ACID VACCINE DELIVERY AND PREPARATION THEREOF
#4ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION
#5THERMOSTABLE MUCOSAL VACCINE COMPOSITIONS AND METHODS
#6NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF
#7COMPOSITIONS, METHODS, AND USES FOR POLYNUCLEOTIDE FORMULATIONS FOR DRYING AND PROLONGED STORAGE
#8SELF-REPLICATING RNA VACCINES AND METHODS OF USE
#9STABILIZATION OF VIRUS-BASED THERAPEUTIC AGENT
#10MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY
#11SALMONELLA FREE EGG PRODUCTION METHODS AND SYSTEMS
#12COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF RABIES VIRUS INFECTION
#13RABIES G PROTEIN AND USES THEREOF
#14SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES
#15NOVEL REOVIRUS-BASED VACCINE PLATFORM AND USE THEREOF
#16METHODS FOR GENERATING FUNCTIONAL SELF-REPLICATING RNA MOLECULES
#17MONOPHOSPHORYL LIPID ADJUVANT (MPLA) COMPOSITIONS, VACCINE COMPOSITIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME
#18METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES
#19USE OF INTERFERON AS AN ADJUVANT IN VACCINES
#20NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE
#21MULTIVALENT VIRAL PARTICLES
#22Peptide VLP-Based Vaccines
#23RABIES VIRUS VACCINE
#24IMMUNE CHECKPOINT MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE
#25APPLICATION OF ARTIFICIALLY SYNTHESIZED CPG SINGLE-STRANDED DEOXYOLIGONUCLEOTIDE IN VACCINES
#26METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA
#27Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
#28ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION
#29Methods of detection and removal of rhabdoviruses from cell lines
#30COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT
#31VIRAL GUIDE RNA DELIVERY
#32VACCINE COMPOSITIONS, METHODS, AND USES THEREOF
#33HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT
#34CORONAVIRUS VACCINE COMPOSITIONS AND METHODS OF USE
#35CPG ODN HAVING IMMUNOREGULARTORY FUNCTION AND USE THEREOF
#36CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS
#37METHOD AND COMPOSITION FOR ENHANCING THE IMMUNE RESPONSE
#38USE OF MEMBRANE INHIBITORS TO ENHANCE VACCINE DEVELOPMENT AGAINST ENVELOPED VIRUSES
#39Artificial nucleic acid molecules for improved protein expression
#40Rabies vaccine
#41LYSSAVIRUS ANTIGEN CONSTRUCTS
#42VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS
#43Methods of detection and removal of rhabdoviruses from cell lines
#44NOVEL LYSSA VIRUS PHOSPHOPROTEINS
#45CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS
#46Artificial nucleic acid molecules for improved protein expression
#47SERUM FREE INTRACELLULAR PATHOGEN VACCINE
#48Multivalent vaccines for rabies virus and coronaviruses
#49HETEROLOGOUS PRIME BOOST VACCINE COMPOSITIONS AND METHODS
#50Rabies composition comprising PIKA adjuvant
#51Artificial nucleic acid molecules for improved protein expression
#52POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT
#53Apparatus for releasably holding a socket
#54ZIKA VIRUS VACCINE
#55VACCINE COMPOSITION FOR PREVENTING RABIES, AND PREPARATION METHOD THEREOF
#56Food safety vaccine to control and reduce in poultry
#57CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS
#58NON-PSYCHOACTIVE CANNABINOIDS AS ADJUVANTS TO ENHANCE MUCOSAL IMMUNITY
#59Attenuated strains of oncolytic rhabdovirus and uses thereof in tumor treatment
#60CHIMERIC VSV VIRUS COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER
#61HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT
#62Compositions and methods for glioblastoma treatment
#63SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#64Parainfluenza virus 5 based vaccines
#65Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
#66Rabies virus vaccine
#67D-glycero-B-D-heptose 1-phosphate (HMP) conjugates and use for targeted immune modulation
#68Rabies vaccine
#69Lyssavirus antigen constructs
#70Methods of detection and removal of rhabdoviruses from cell lines
#71MODIFIED VSV-G AND VACCINES THEREOF
#72Pharmaceutical composition comprising glutatione disulfide and glutathione disulfide S-oxide
#73Apparatus for releasably holding a socket
#74Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
#75Food safety vaccine to control and reduce campylobacter in poultry
#76Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
#77PIV5 AS AN ONCOLYTIC AGENT
#78Zika virus vaccine
#79RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPS)
#80Chimeric VSV virus compositions and methods of use thereof for treatment of cancer
#81Multivalent vaccines for rabies virus and coronaviruses
#82Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto
#83Human antibodies against rabies and uses thereof
#84VACCINE COMPOSITION
#85Compositions and methods for treating viral infections
#86Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
#87Vaccine adjuvant composition comprising inulin particles
#88Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof
#89Thermostable vaccines based on ether lipids and native viral envelope proteins
#90Canine adenovirus vectors
#91Method of Vaccination Comprising a Histone Deacetylase Inhibitor
#92Artificial nucleic acid molecules for improved protein expression
#93Rabies glycoprotein virus-like particles (VLPS)
#94A Rabies Composition Comprising Pika Adjuvant
#95PIV5 as an oncolytic agent
#96Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
#97SMC combination therapy for the treatment of cancer
#98Vaccination response for immunodeficiency disorders or high cortisol
#99Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
#100COMPOSITIONS CONTAINING AMBIENT-TEMPERATURE STABLE, INACTIVATED BUT THERAPEUTICALLY ACTIVE BIOPHARMACEUTICALS & METHODS FOR FORMULATION THEREOF
#101Parainfluenza virus 5 based vaccines
#102Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins
#103Peptide/β-1,3-glucan complex and production method thereof and pharmaceutical composition containing peptide/β-1,3-glucan complex
#104Chimeric VSV virus compositions and methods of use thereof for treatment of cancer
#105Compositions and methods for glioblastoma treatment
#106ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS
#107Methods of detection and removal of rhabdoviruses from cell lines
#108Nasal mucosal vaccine composition
#109Mucosal vaccine composition
#110Rabies vaccine
#111Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
#112PAN-LYSSAVIRUS VACCINES AGAINST RABIES
#113Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof
#114Methods of generating robust passive and active immune responses
#115COMPOSITIONS AND METHODS OF MODULATING AN IMMUNE RESPONSE
#116ASSAY FOR ANALYSES OF RABIES VIRUS GLYCOPROTEIN
#117Formulations for non-invasive delivery of active proteins to an animal or human
#118Recombinant novirhabdovirus usable as an antigen vector
#119Method for purifying the rabies virus
#120Immunization with rabies virus vector expressing foreign protein antigen
#121PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN
#122Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
#123ADJUVANTED FORMULATIONS OF RABIES VIRUS IMMUNOGENS
#124Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
#125PIV5 as oncolytic agent
#126Attenuated recombinant vesicular stomatitis viruses comprising modified mutant matrix proteins
#127COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
#128Vaccine adjuvant composition comprising inulin particles
#129Use of the PACAP as a molecular adjuvant for vaccines
#130Intra-testicular Injection of Immunogens
#131Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G
#132Multivalent vaccines for rabies virus and filoviruses
#133Method of vaccination comprising a histone deacetylase inhibitor
#134Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
#135Rabies glycoprotein virus-like particles (VLPS)
#136NON-SELF T-CELL EPITOPE FUSED TO AN ANTIBODY THAT RECOGNISES A TUMOUR-SPECIFIC CELL-SURFACE RECEPTOR AND USES THEREOF
#137Compositions and methods for glioblastoma treatment
#138Stabilizing excipient for inactivated whole virus vaccine
#139TRANSGENIC ALGAE FOR DELIVERING ANTIGENS TO AN ANIMAL
#140Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
#141anti-HPV drug and its application in preparing medicines for treatment of HPV (human papilloma virus) infection
#142Lipid Based Adjuvants for DNA Plasmids
#143Pan-lyssavirus vaccines against rabies
#144HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF
#145Adjuvanted rabies vaccine with improved viscosity profile
#146Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#147IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES
#148COMPOSITION
#149Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
#150PARAPOXVIRUS VECTORS
#151Rabies virus-based recombinant immunocontraceptive compositions and methods of use
#152Replication-defective flavivirus vaccines and vaccine vectors
#153Stabilizing excipient for inactivated whole virus vaccine
#154Rabies virus vector systems and compositions and methods thereof
#155Attenuated live triple G protein recombinant rabies virus vaccine for pre- and post-exposure prophylaxis of rabies
#156RABIES CURE
#157Human antibodies against rabies and uses thereof
#158VIRAL VACCINE VECTORS
#159Polyinosinic acid-polycytidylic acid-based adjuvant
#160Rabies Vaccine
#161Mutant viruses and uses thereof
#162Method for purifying the rabies virus
#163NOVEL METHODS AND INTERFERON DEFICIENT SUBSTRATES FOR THE PROPAGATION OF VIRUSES
#164Adaptation of Pitman Moore strain of rabies virus to primary chick embryo fibroblast cell cultures
#165ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS
#166Rabies vaccine
#167Chemically defined vaccine stabiliser
#168Methods for the propagation of modified influenza viruses in embryonated eggs
#169DNA vaccine against North American spring viremia of carp virus
#170Transgenic algae for delivering antigens to an animal
#171Cationic lipid-mediated enhancement of nucleic acid immunization of cats
#172Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#173Human antibodies against rabies and uses thereof
#174Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines
#175Raccoon poxvirus expressing rabies glycoproteins
#176Chimeric G protein based rabies vaccine
#177Pharmaceutical preparation that can be administered orally for treating fish, production method for said preparation and use of the latter
#178Rhabdoviral N-Fusion Proteins as Carrier for Foreign Antigens
#179Rabies virus vector systems and compositions and methods thereof
#180Use of penetration enhancers and barrier disruption methods to enhance the immune response of an antigen
#181Chimeric lyssavirus nucleic acids and polypeptides
#182Medicine for Treating Tumor and Use Therefor in Preparation of the Medicaments for Treating Tumor
#183Vaccines against vesicular stomatitis
#184Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant
#185Mutant G Genes of the Trout Viral Haemorrhagic Septicaemia Virus (Vhsv) and Applications Thereof
#186Gene Construction, Vector and Dna Vaccine for the Vaccination of Aquatic Animals
#187Immunologically enhanced recombinant vaccines
#188Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
#189Polyinosinic acid-polycytidylic acid-based adjuvant
#190Mutant vesicular stomatitis viruses and uses thereof
#191Rabies vaccine
#192Antigenic peptides of rabies virus and uses thereof
#193Compositions and methods for delivery of genetic material
#194Methods for inducing an immune response via oral administration of an adenovirus
#195Use of modified novirhabdoviruses to obtain vaccines
#196Vaccination of skunks and/or mongooses against rabies
#197IHNV G protein for immune stimulation
#198Chimeric lyssavirus nucleic acids and polypeptides
#199Methods and interferon deficient substrates for the propagation of viruses
#200Cationic lipid-mediated enhancement of nucleic acid immunization of cats